|
acupuncture |
24 |
|
apoptosis |
18 |
|
breast cancer |
14 |
|
insomnia |
14 |
|
menopause |
13 |
|
chinese medicine |
12 |
|
electroacupuncture |
12 |
|
sleep |
12 |
|
chemobrain |
11 |
|
self-acupressure |
11 |
|
self-help |
11 |
|
traditional chinese medicine |
11 |
|
erxian decoction |
10 |
|
5-fluorouracil |
9 |
|
acupressure |
9 |
|
chinese |
9 |
|
depression |
9 |
|
randomized controlled trial |
9 |
|
rct |
9 |
|
alzheimer's disease |
8 |
|
animal experiment |
8 |
|
appswe/ps1de9 |
8 |
|
aquaporin 9 |
8 |
|
beta-amyloid |
8 |
|
chinese herbal medicine |
8 |
|
family caregivers |
8 |
|
medicinal plants |
8 |
|
aqp5 |
7 |
|
bioactive compounds |
7 |
|
complementary and alternative medicine |
7 |
|
dendrobium officinale |
7 |
|
extraction |
7 |
|
geriatrics |
7 |
|
major depressive disorder |
7 |
|
meta-analysis |
7 |
|
multiple reaction monitoring |
7 |
|
oxidative stress |
7 |
|
polysaccharides |
7 |
|
proanthocyanidins |
7 |
|
self‐administered acupressure |
7 |
|
sjogren's syndrome |
7 |
|
stress |
7 |
|
tumor‐shrinking decoction |
7 |
|
ultra‐pressure liquid chromatography coupled tandem mass spectrometry |
7 |
|
benzodiazepine discontinuation |
6 |
|
caregiver stress |
6 |
|
chemotherapy |
6 |
|
clinical trials |
6 |
|
colorectal cancer |
6 |
|
complementary medicine |
6 |
|
diabetes & endocrinology |
6 |
|
diabetic nephropathy & vascular disease |
6 |
|
fatigue |
6 |
|
health-related quality of life |
6 |
|
herbal medicine |
6 |
|
ht-29 cells |
6 |
|
intervention |
6 |
|
intestinal mucositis |
6 |
|
nephrology |
6 |
|
p-pkb |
6 |
|
pomegranate peel ellagitannins |
6 |
|
randomized controlled trial (rct) |
6 |
|
self-administered acupressure |
6 |
|
sham |
6 |
|
sleep hygiene |
6 |
|
steroidogenic |
6 |
|
uncaria rhynchophylla |
6 |
|
withdrawal |
6 |
|
antipsychotic agents - administration and dosage - therapeutic use |
5 |
|
antipsychotics |
5 |
|
antitumorigenicity |
5 |
|
auricular acupressure |
5 |
|
cancer cell culture |
5 |
|
cell invasion |
5 |
|
cell migration |
5 |
|
cell motility |
5 |
|
chemotherapy-associated insomnia |
5 |
|
chinese medicinal formula |
5 |
|
chinese medicine formula |
5 |
|
colon cancer |
5 |
|
constituent fractions |
5 |
|
cytokines |
5 |
|
dna damage |
5 |
|
drugs, chinese herbal - therapeutic use |
5 |
|
er-xian decoction |
5 |
|
etoposide |
5 |
|
ficus virens |
5 |
|
gut microbiota |
5 |
|
hepatocellular carcinoma |
5 |
|
herb-drug interactions - physiology |
5 |
|
holistic |
5 |
|
hot flushes |
5 |
|
hyperprolactinemia |
5 |
|
medicine, chinese traditional - adverse effects - utilization |
5 |
|
mild cognitive impairment |
5 |
|
mir-23a |
5 |
|
mucositis |
5 |
|
neuroplasticity |
5 |
|
novel approach |
5 |
|
peony-glycyrrhiza decoction (pgd) |
5 |
|
quality of life |
5 |
|
schizophrenia - drug therapy - epidemiology |
5 |
|
standard chemicals |
5 |
|
systematic review |
5 |
|
tian xian liquid |
5 |
|
topoisomerase 1 |
5 |
|
trigeminal nerve stimulation |
5 |
|
acupoint |
4 |
|
acupuncture analgesia |
4 |
|
adiponectin |
4 |
|
adipor |
4 |
|
adverse events |
4 |
|
alcoholic liver injury |
4 |
|
ampk |
4 |
|
antioxidant |
4 |
|
assessment |
4 |
|
auricular acupoint |
4 |
|
auricular acupuncture |
4 |
|
beige cell |
4 |
|
berberine |
4 |
|
cessation rate of sleeping medications |
4 |
|
chinese medicines |
4 |
|
coptidis rhizome aqueous extract |
4 |
|
d2 receptors |
4 |
|
diabetes |
4 |
|
dopamine |
4 |
|
eukaryotic elongation factor 2 |
4 |
|
foods |
4 |
|
ginsenoside rg1 |
4 |
|
granulocytic‐myeloid‐derived suppressor cell‐like population |
4 |
|
leptin |
4 |
|
liver diseases |
4 |
|
massage |
4 |
|
mechanism |
4 |
|
nascent protein synthesis |
4 |
|
neuroinflammation |
4 |
|
obesity |
4 |
|
osteoporosis |
4 |
|
phytochemical |
4 |
|
placebo |
4 |
|
rating scale |
4 |
|
residual insomnia |
4 |
|
vascular endothelial growth factor |
4 |
|
white adipocyte |
4 |
|
cancer chemotherapy |
3 |
|
cholesterol blood level |
3 |
|
clinical trial |
3 |
|
clozapine |
3 |
|
cognition dysfunction |
3 |
|
cytokines and epigenetics |
3 |
|
down regulation |
3 |
|
drugs, chinese herbal - administration and dosage - adverse effects |
3 |
|
electronic prescribing |
3 |
|
gegen qinlian decoction |
3 |
|
health information technology |
3 |
|
herb-drug interaction |
3 |
|
humans |
3 |
|
lipid blood level |
3 |
|
male |
3 |
|
mmp-2 |
3 |
|
neuroprotection |
3 |
|
pharmacokinetics |
3 |
|
postpartum |
3 |
|
questionnaire |
3 |
|
questionnaire survey |
3 |
|
radix scutellariae |
3 |
|
reflexology |
3 |
|
renal carcinoma |
3 |
|
survey |
3 |
|
treatment outcome |
3 |
|
tumor growth inhibition |
3 |
|
wait-list controlled |
3 |
|
young adult |
3 |
|
18beta-glycyrrhetinic acid |
2 |
|
adolescent |
2 |
|
adult |
2 |
|
apoptotic pathways |
2 |
|
bdnf |
2 |
|
benign prostatic hyperplasia (bph) |
2 |
|
brain derived neurotrophic factor |
2 |
|
c-fos |
2 |
|
carbamazepine |
2 |
|
chronic prostatitis/chronic pelvic pain syndrome |
2 |
|
classical and atypical antipsychotics |
2 |
|
cognitive impairment |
2 |
|
cortisol |
2 |
|
drug therapy, combination |
2 |
|
drugs, chinese herbal - administration & dosage - adverse effects |
2 |
|
electroconvulsive therapy |
2 |
|
endurance |
2 |
|
essential oil |
2 |
|
fatigue - drug therapy |
2 |
|
female |
2 |
|
ginkgo biloba |
2 |
|
glutamate |
2 |
|
herbal supplement |
2 |
|
hydrocortisone - blood |
2 |
|
integrative medicine |
2 |
|
intracellular calcium |
2 |
|
liquiritigenin |
2 |
|
lung cancer |
2 |
|
maximal oxygen uptake |
2 |
|
metabolism |
2 |
|
mitochondria |
2 |
|
mpp+ |
2 |
|
oxygen consumption - drug effects |
2 |
|
paeoniflorin |
2 |
|
pc12 cells |
2 |
|
physical endurance - drug effects |
2 |
|
pituitary adenoma |
2 |
|
placebos |
2 |
|
post-stroke depression |
2 |
|
prostatic hyperplasia - drug therapy |
2 |
|
randomized controlled trials as topic |
2 |
|
ras/erks |
2 |
|
review |
2 |
|
rhodiola |
2 |
|
ros |
2 |
|
ros/mapks |
2 |
|
schizophrenia |
2 |
|
serotonin |
2 |
|
stat-3 |
2 |
|
testosterone |
2 |
|
testosterone - blood |
2 |
|
unipolar depression |
2 |
|
18β-glycyrrhetinic acid |
1 |
|
2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1h-3-benzazepine - analogs & derivatives - pharmacology |
1 |
|
3-methyl-6-chloro-7,8-hydroxy-1-(3-methylphenyl)-2, 3,4,5-tetrahydro-1h-3-benzazepine |
1 |
|
5-ht2a receptor |
1 |
|
5-ht3 receptor antagonist |
1 |
|
5-hydroxyindoleacetic acid (5-hiaa) |
1 |
|
5-ling granule |
1 |
|
acetic acids - administration & dosage |
1 |
|
acoustic startle reflex |
1 |
|
acoustic stimulation |
1 |
|
acupuncture points |
1 |
|
acupuncture therapy |
1 |
|
acupuncture therapy - adverse effects |
1 |
|
administration, oral |
1 |
|
adolescents |
1 |
|
affinity labels - pharmacology |
1 |
|
aged |
1 |
|
agonist |
1 |
|
akt |
1 |
|
albiflorin |
1 |
|
aluminum |
1 |
|
aluminum compounds - toxicity |
1 |
|
amines |
1 |
|
amygdala - drug effects |
1 |
|
amygdala - physiology |
1 |
|
amygdala kindling |
1 |
|
amyloid beta-peptides - biosynthesis |
1 |
|
analgesics, non-narcotic - therapeutic use |
1 |
|
analysis of variance |
1 |
|
animal models |
1 |
|
animals |
1 |
|
anti-anxiety agents - pharmacology - therapeutic use |
1 |
|
anti-anxiety agents - therapeutic use |
1 |
|
anti-substance abuse |
1 |
|
anticancer |
1 |
|
anticonvulsant |
1 |
|
anticonvulsants - administration & dosage |
1 |
|
anticonvulsants - adverse effects - therapeutic use |
1 |
|
anticonvulsants - pharmacology |
1 |
|
anticonvulsants - toxicity |
1 |
|
antidementia |
1 |
|
antidepressant |
1 |
|
antidepressive agents - administration and dosage - adverse effects |
1 |
|
antidepressive agents - adverse effects - blood - pharmacokinetics |
1 |
|
antidepressive agents - adverse effects - therapeutic use |
1 |
|
antidepressive agents - therapeutic use |
1 |
|
antidepressive agents, second-generation - administration and dosage |
1 |
|
antidepressive agents, second-generation - pharmacology |
1 |
|
antimanic agents - adverse effects - therapeutic use |
1 |
|
antimanic agents - therapeutic use |
1 |
|
antioxidants - pharmacology |
1 |
|
antipsychotic agents - blood - therapeutic use |
1 |
|
antipsychotic agents - pharmacokinetics - therapeutic use |
1 |
|
antipsychotic agents - therapeutic use |
1 |
|
anxiety |
1 |
|
anxiolytic |
1 |
|
apoptosis - drug effects |
1 |
|
area under curve |
1 |
|
autonomic nervous system - physiology |
1 |
|
avoidance learning - drug effects |
1 |
|
azides - pharmacology |
1 |
|
azoles - pharmacology |
1 |
|
bax |
1 |
|
bcl-2 |
1 |
|
bcl-2-associated x protein - metabolism |
1 |
|
behavior, animal - drug effects |
1 |
|
behavioral effects |
1 |
|
benzodiazepine partial inverse agonist |
1 |
|
benzodiazepines - adverse effects - blood - pharmacokinetics |
1 |
|
benzodiazepines - pharmacology |
1 |
|
berberine - analogs and derivatives - pharmacology |
1 |
|
bipolar depression |
1 |
|
bipolar disorder |
1 |
|
bipolar disorder - complications - diagnosis - drug therapy |
1 |
|
bipolar disorder - diagnosis - drug therapy - psychology |
1 |
|
bipolar disorder - drug therapy |
1 |
|
bipolar disorders |
1 |
|
blood carbamazepine levels |
1 |
|
body weight |
1 |
|
body weight - drug effects - physiology |
1 |
|
brain |
1 |
|
brain - pathology |
1 |
|
brief psychiatric rating scale |
1 |
|
calcium |
1 |
|
camkii |
1 |
|
cancer |
1 |
|
carbamazepine - adverse effects - therapeutic use |
1 |
|
carbamazepine - pharmacology |
1 |
|
carbamazepine - therapeutic use |
1 |
|
carbamazepine - toxicity |
1 |
|
cardiology |
1 |
|
cell count - methods |
1 |
|
cell survival - drug effects - physiology |
1 |
|
cells, cultured |
1 |
|
cerebral cortex - cytology |
1 |
|
cerebral cortex - drug effects - metabolism |
1 |
|
chemoresistance |
1 |
|
chlorides - toxicity |
1 |
|
chronic disease |
1 |
|
chronic unpredictable stress |
1 |
|
clinical perspectives |
1 |
|
clomipramine |
1 |
|
clozapine - adverse effects - analogs & derivatives - blood - pharmacokinetics |
1 |
|
clozapine - analogs & derivatives - blood - therapeutic use |
1 |
|
coalmining disaster |
1 |
|
cognition disorders - drug therapy - etiology |
1 |
|
cognitive behavioral therapy (cbt) |
1 |
|
combined modality therapy |
1 |
|
constipation - chemically induced |
1 |
|
cross-tolerance |
1 |
|
cultural psychiatry |
1 |
|
cultured cortical neurons |
1 |
|
cyclohexanecarboxylic acids |
1 |
|
dceas |
1 |
|
dementia - drug therapy |
1 |
|
dense cranial electroacupuncture stimulation |
1 |
|
dense cranial electroacupuncture stimulation (dceas) |
1 |
|
depression disorders |
1 |
|
depressive disorder - diagnosis - psychology - therapy |
1 |
|
depressive disorder - drug therapy |
1 |
|
depressive disorder, major - diagnosis - drug therapy - psychology |
1 |
|
depressive disorder, major - diagnosis - psychology - therapy |
1 |
|
depressive disorder, major - therapy |
1 |
|
diagnostic and statistical manual of mental disorders |
1 |
|
dipsacus asper |
1 |
|
disasters |
1 |
|
disease models, animal |
1 |
|
dizocilpine maleate - administration & dosage |
1 |
|
dizziness - chemically induced |
1 |
|
dopamine - metabolism |
1 |
|
dopamine agonists - pharmacology |
1 |
|
dopamine d1-like receptor |
1 |
|
dopamine receptor |
1 |
|
dopamine system |
1 |
|
dose-response relationship, drug |
1 |
|
double-blind method |
1 |
|
drug interactions |
1 |
|
drug resistance |
1 |
|
drug tolerance |
1 |
|
drug tolerance - physiology |
1 |
|
drugs, chinese herbal - adverse effects - therapeutic use |
1 |
|
drugs, chinese herbal - pharmacology |
1 |
|
drugs, chinese herbal - pharmacology - therapeutic use |
1 |
|
ebselen |
1 |
|
electroacupunctu |
1 |
|
electroacupuncture - methods |
1 |
|
electroconvulsive therapy (ect) |
1 |
|
electroconvulsive therapy - methods |
1 |
|
electroencephalography - drug effects |
1 |
|
elevated plus-maze test |
1 |
|
embryo, mammalian |
1 |
|
endpoint determination |
1 |
|
enhanced single prolonged stress |
1 |
|
entropy |
1 |
|
epilepsy - drug therapy - mortality - physiopathology |
1 |
|
erk |
1 |
|
estrogen deprivation |
1 |
|
estrogen therapy |
1 |
|
explanatory model |
1 |
|
exploratory behavior - drug effects |
1 |
|
first-episode psychosis |
1 |
|
fluvoxamine |
1 |
|
fluvoxamine - pharmacology |
1 |
|
follow-up |
1 |
|
follow-up studies |
1 |
|
fourier analysis |
1 |
|
free and easy wanderer plus |
1 |
|
functional disability |
1 |
|
gaba-a receptor agonists |
1 |
|
gabapentin |
1 |
|
gamma-aminobutyric acid |
1 |
|
gastrodin |
1 |
|
gene expression regulation, developmental - drug effects |
1 |
|
glutamic acid - adverse effects |
1 |
|
glycogen synthase kinase 3 - antagonists & inhibitors - metabolism |
1 |
|
glycogen synthase kinase-3β |
1 |
|
half-life |
1 |
|
haloperidol |
1 |
|
haloperidol - pharmacokinetics - therapeutic use |
1 |
|
healthy volunteers |
1 |
|
heart rate - physiology |
1 |
|
heart rate variability |
1 |
|
helplessness, learned |
1 |
|
herbal medicines |
1 |
|
hippocampal stem cell |
1 |
|
hippocampus |
1 |
|
hippocampus - drug effects - metabolism |
1 |
|
hormones |
1 |
|
human liver microsomes |
1 |
|
hypothalamic-pituitary-adrenal (hpa) axis |
1 |
|
hypothyroidism |
1 |
|
hypothyroidism - complications - diagnosis |
1 |
|
il-1β |
1 |
|
in vivo transcranial two-photon imaging |
1 |
|
inflammation |
1 |
|
injections, intraperitoneal |
1 |
|
jie-yu pill |
1 |
|
keap1/nrf2 |
1 |
|
kindling |
1 |
|
kindling, neurologic - drug effects |
1 |
|
kindling, neurologic - drug effects - physiology |
1 |
|
l-stepholidine |
1 |
|
lamotrigine |
1 |
|
lethality |
1 |
|
levetiracetam |
1 |
|
lily bulb |
1 |
|
lithium |
1 |
|
lithium carbonate - therapeutic use |
1 |
|
long-term care |
1 |
|
magnetic resonance imaging |
1 |
|
major depression |
1 |
|
manganese-enhanced magnetic resonance imaging (memri) |
1 |
|
mania |
1 |
|
maze learning - drug effects |
1 |
|
mdl 11,939 |
1 |
|
menopause syndrome |
1 |
|
mental disorders - drug therapy |
1 |
|
metabolic clearance rate |
1 |
|
mice |
1 |
|
middle aged |
1 |
|
mk-801 |
1 |
|
morris water maze test |
1 |
|
negative symptoms |
1 |
|
neuroleptic |
1 |
|
neurons - drug effects |
1 |
|
neurons - drug effects - metabolism |
1 |
|
neuroprotective agents - pharmacology |
1 |
|
neurotrophins |
1 |
|
nitric oxide |
1 |
|
norclozapine |
1 |
|
obsessive compulsive disorder (ocd) |
1 |
|
obsessive-compulsive disorder |
1 |
|
obsessive-compulsive disorder - diagnosis - drug therapy - therapy |
1 |
|
olanzapine |
1 |
|
ondansetron |
1 |
|
ondansetron - pharmacokinetics - therapeutic use |
1 |
|
open field test |
1 |
|
organoselenium compounds - pharmacology |
1 |
|
p53 signaling pathways |
1 |
|
palliative care |
1 |
|
paroxetine |
1 |
|
passive avoidance task |
1 |
|
patient dropouts |
1 |
|
phytotherapy |
1 |
|
pilot trial |
1 |
|
piperidines - pharmacology - therapeutic use |
1 |
|
piracetam - analogs & derivatives - pharmacology |
1 |
|
plant extracts - therapeutic use |
1 |
|
plants, medicinal - chemistry |
1 |
|
platelet |
1 |
|
polyherbal preparation |
1 |
|
polyphenols |
1 |
|
polysomnography (psg) |
1 |
|
positive symptoms |
1 |
|
post-traumatic stress disorder |
1 |
|
poststroke depression |
1 |
|
posttraumatic stress disorder (ptsd) |
1 |
|
predictive value of tests |
1 |
|
pretreatment |
1 |
|
prospective studies |
1 |
|
protein kinase inhibitors - pharmacology |
1 |
|
proto-oncogene proteins c-bcl-2 - metabolism |
1 |
|
psychiatric disorders |
1 |
|
psychology, pathological. |
1 |
|
psychopharmacology. |
1 |
|
psychotic disorders - therapy |
1 |
|
psychotropic drugs. |
1 |
|
ptsd |
1 |
|
pubmed |
1 |
|
quetiapine |
1 |
|
radix rehmanniae extract |
1 |
|
random allocation |
1 |
|
rat |
1 |
|
rats |
1 |
|
rats, sprague-dawley |
1 |
|
receptor, serotonin, 5-ht1a - metabolism |
1 |
|
receptor, serotonin, 5-ht2a - physiology |
1 |
|
receptors, dopamine d1 - agonists |
1 |
|
recombinant cyps |
1 |
|
recurrence |
1 |
|
rehabilitation |
1 |
|
relapse |
1 |
|
ro15-4513 |
1 |
|
sample entropy |
1 |
|
schizophrenia - blood - drug therapy |
1 |
|
schizophrenia - diagnosis - drug therapy |
1 |
|
seizures - drug therapy - physiopathology |
1 |
|
serotonergic system |
1 |
|
serotonin reuptake inhibitors (sris) |
1 |
|
serum concentration |
1 |
|
severity of illness index |
1 |
|
sexual hormone |
1 |
|
single unit recording |
1 |
|
skf83959 |
1 |
|
sleep disorders - etiology |
1 |
|
sleep disorders - therapy |
1 |
|
slow oscillation |
1 |
|
spatial behavior - drug effects |
1 |
|
startle |
1 |
|
startle reaction - drug effects |
1 |
|
startle reaction - drug effects - physiology |
1 |
|
statistics as topic |
1 |
|
stress disorders, post-traumatic - blood - epidemiology - etiology - pathology - psychology |
1 |
|
stress disorders, post-traumatic - drug therapy - etiology |
1 |
|
stress, psychological - complications |
1 |
|
substance-related disorders - drug therapy |
1 |
|
systematic reviews |
1 |
|
thyroid hormone |
1 |
|
thyroid-stimulating hormone |
1 |
|
tiapride |
1 |
|
tics |
1 |
|
time factors |
1 |
|
tolerance |
1 |
|
tourette syndrome |
1 |
|
transcutaneous electrical acupoint stimulation (teas) |
1 |
|
transcutaneous electrical nerve stimulation (tens) |
1 |
|
triazines - administration & dosage |
1 |
|
tumor |
1 |
|
uterus |
1 |
|
vitamin e |
1 |
|
vitamin e - pharmacology |
1 |
|
β-amyloid protein |
1 |
